Subscribe: Pharmaceutical News
Preview: Pharmaceutical News

Pharmaceutical News

Pharmaceuticals news continually updated from thousands of sources around the net.

Copyright: Copyright 2017, Topix

WESCO International, Inc. (WCC) EPS Estimated At $0.98; Highbridge...

Wed, 17 Jan 2018 12:08:56 GMT

Analysts expect WESCO International, Inc. to report $0.98 EPS on January, 25.They anticipate $0.02 EPS change or 2.08% from last quarter's $0.96 EPS. WCC's profit would be $46.06M giving it 16.88 P/E if the $0.98 EPS is correct.

Argyle Capital Management Has Boosted Its Mckesson (MCK) Holding;...

Wed, 17 Jan 2018 07:46:50 GMT

Among 4 analysts covering Exactech , 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive.

Israel imposes $22-million fine on pharmaceutical firm

Wed, 17 Jan 2018 03:41:26 GMT

The State Prosecutor's Office in Israel has fined Israel-based Teva Pharmaceutical Industries Ltd. $22 million for its involvement in corruption in Eastern Europe and Mexico, reported citing Channel 12. According to the findings of an investigation, the firm made "corrupt payments" to public employees in Russia and Ukraine and improper payments in Mexico, and generated $220 million in profits.

McKesson Co. (MCK) Shares Bought by Cwm LLC

Tue, 16 Jan 2018 23:03:27 GMT

Cwm LLC raised its stake in shares of McKesson Co. by 24,866.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission .

Merck Extends Its Lung Cancer Lead With New Combo Trial: Gadfly

Tue, 16 Jan 2018 20:40:10 GMT

The company announced on Monday that a combination of its key immune-boosting cancer drug Keytruda and an older chemotherapy helped newly diagnosed lung cancer patients survive significantly longer in a large trial -- a groundbreaking result that comes months earlier than expected. Bristol-Myers Squibb & Co.'

Merck Extends Its Lung Cancer Lead 2 hours ago

Tue, 16 Jan 2018 20:40:09 GMT

Max Nisen is a Bloomberg Gadfly columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.

Teva Pharmaceutical Industries (TEVA) Cut to Sell at Zacks Investment Research

Tue, 16 Jan 2018 18:20:20 GMT

According to Zacks, "Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva's shares have underperformed the generic industry in the past one year.

Mylan (MYL) Upgraded to Hold at Zacks Investment Research

Tue, 16 Jan 2018 18:20:19 GMT

According to Zacks, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity.

Zacks Investment Research Upgrades Mylan (MYL) to "Hold"

Tue, 16 Jan 2018 18:20:18 GMT

According to Zacks, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity.

2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?

Tue, 16 Jan 2018 15:52:09 GMT

Significant scientific and technological breakthroughs, combined with unabated M&A appetite and tax reform, provide fertile ground for biotech gains in 2018. Investing is a never-ending story, a matter of keeping up to date and anticipating important developments.

Is The New Impax/Amneal An Interesting Pairing?

Tue, 16 Jan 2018 11:16:35 GMT

However, I caution that generic revenue can be unpredictable, and I would wait for a larger margin of safety before establishing a position. In October of 2017, following a meteoric rise in its share price, Impax Labs announced a merger agreement with private company Amneal to diversify revenue streams and increase negotiating leverage with group purchasing organizations .

From drug pricing and 'biosimilars' to opioids and culture - a wrap ...

Tue, 16 Jan 2018 07:00:43 GMT

It could be weeks or a year before the deals that biotech executives and financiers started at last week's 36th J.P. Morgan Healthcare Conference come to fruition.

Lannett Company, Inc. (LCI) Given Consensus Rating of "Hold" by Brokerages

Tue, 16 Jan 2018 02:38:06 GMT

Shares of Lannett Company, Inc. have been assigned an average rating of "Hold" from the eight analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the company.

Impax Laboratories (IPXL) Upgraded at Zacks Investment Research

Mon, 15 Jan 2018 22:05:15 GMT

According to Zacks, "Impax's epinephrine auto-injector sales have picked up and the company has 18 ANDAs pending FDA approval. Impax's generics pipeline should be able to take advantage of the upcoming patent expirations amid competitive and pricing pressure, which is expected to persist through 2017.

Teva Announces U.S. FDA Approval of TRISENOX (arsenic trioxide)...

Mon, 15 Jan 2018 17:29:20 GMT

Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has approved the use of TRISENOX injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia whose APL is characterized by the presence of the t translocation or PML/RAR-alpha gene expression. The approval was based on a Priority Review by the FDA on data from published scientific literature and a review of Teva's global safety database for arsenic trioxide.

Teva to pay NIS 75 million to Israel authorities to settle foreign bribe claims

Mon, 15 Jan 2018 12:50:17 GMT

Deal takes into account the pharmaceutical company's financial plight, and the fact that it has already been penalized by the US for the infractions Teva Pharmaceutical Industries Ltd. has agreed to pay NIS 75 million in fines to Israeli authorities as part of a settlement in which the drug-maker admitted to paying bribes in Russia, Ukraine and Mexico to increase sales. The agreement with the State Attorney's office, comes after the company agreed to pay more than $519 million to settle the same charges with US authorities in 2016.

The biggest company in California that you haven't heard about

Mon, 15 Jan 2018 08:23:38 GMT

For example, here's a question that stumps even Californians who know the state well: What's the second-richest company in California after Apple? Never heard of it? You're not alone. McKesson is "a massive corporation hiding in plain sight," Fortune wrote recently.